CLAIMS

- A polypeptide, characterized in that:
 - it is constituted by a unique or repeated peptide motif;
- it comprises an amino acid sequence constituted by one or more different antibody fragment(s); and
 - it is capable of penetrating into cells.
- A polypeptide according to claim 1, characterized in that it comprises a fragment of a heavy antibody chain.
 - 3. A polypeptide according to claim 2, characterized in that it comprises all or a portion of the CDR3 region of an antibody.
- 4. A polypeptide according to claim 2, characterized in that it comprises all or a portion of the CDR2 region of an antibody.
 - 5. A polypeptide according to claim 3 or claim 4, characterized in that it comprises all or a portion of the CDR3 region and all or a portion of the CDR2 region of an antibody.

20

30

- 6. A polypeptide according to claim 5, characterized in that it essentially consists of a fusion between the CDR3 region of an antibody and the CDR2 region of an antibody.
- 25 7. A polypeptide according to any one of the preceding claims, characterized in that it comprises at most 100 amino acids.
 - 8. A polypeptide according to claim 7, characterized in that it comprises 3 to 60 amino acids, preferably 3 to 30 amino acids.
 - 9. A polypeptide according to any one of the preceding claims, characterized in that the antibody fragment

is a fragment of an antibody capable of penetrating into cells.

10. A polypeptide according to claim 9, characterized in that the antibody fragment is a fragment of a polyreactive antibody.

5

15

30

- 11. A polypeptide according to claim 10, characterized in that the antibody fragment is a fragment of an anti-DNA antibody.
- 12. A polypeptide according to claim 1, characterized in that it comprises a region with a sequence selected from SEQ ID n° 1, 2, 3 and 8, or any functional homologue.
 - 13. A polypeptide according to claim 1, characterized in that it is also capable of causing a substance to penetrate into a cell.
 - 14. Use of a polypeptide according to any one of the preceding claims, to transfer substances into cells.
- 15. A polypeptide according to any one of claims 1 to 13, characterized in that it is coupled to a substance.
 - 16. A vector for transferring a substance into a cell, characterized in that it comprises a polypeptide according to any one of claims 1 to 13 to which said substance is coupled.
- 25 17. A vector according to claim 16, characterized in that the coupling is a covalent coupling.
 - 18. A vector according to claim 17, characterized in that coupling is effected by a maleimide, succinimide, peptide, disulphide, amine, acid, biotin-streptavidin or p-benzoquinone type bond.
 - 19. A vector according to claim 16, characterized in that said substance is a nucleic acid.

- 20. A vector according to claim 16, characterized in that said substance is a protein.
- 21. A vector according to claim 16, characterized in that said substance is a drug.
- 5 22. A vector according to claim 16, characterized in that said substance is an antigen.
 - 23. A eukaryotic cell containing a polypeptide according to any one of claims 1 to 20.
- 24. A eukaryotic cell containing a vector according to Claim 16.
 - 25. A method for transferring a substance into a cell *in* vitro, comprising:
 - coupling said substance to a polypeptide as defined in claim 1, and
- incubating the cell with the product of said coupling.
 - 26. A pharmaceutical composition comprising a vector according to claim 16 in which the substance is an active principle of a drug, in association with a physiologically acceptable vehicle.

20

27. A vaccine comprising a vector according to claim 16 in which the substance is an antigen, in association with a physiologically acceptable vehicle.